Cargando…

Molecular profiling of patient-derived breast cancer xenografts

INTRODUCTION: Identification of new therapeutic agents for breast cancer (BC) requires preclinical models that reproduce the molecular characteristics of their respective clinical tumors. In this work, we analyzed the genomic and gene expression profiles of human BC xenografts and the corresponding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reyal, Fabien, Guyader, Charlotte, Decraene, Charles, Lucchesi, Carlo, Auger, Nathalie, Assayag, Franck, De Plater, Ludmilla, Gentien, David, Poupon, Marie-France, Cottu, Paul, De Cremoux, Patricia, Gestraud, Pierre, Vincent-Salomon, Anne, Fontaine, Jean-Jacques, Roman-Roman, Sergio, Delattre, Olivier, Decaudin, Didier, Marangoni, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496128/ https://www.ncbi.nlm.nih.gov/pubmed/22247967 http://dx.doi.org/10.1186/bcr3095

Ejemplares similares

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
por: de Plater, L, et al.
Publicado: (2010)

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization
por: Vallerand, David, et al.
Publicado: (2016)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts
por: de Plater, Ludmilla, et al.
Publicado: (2014)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas
por: Vincent-Salomon, Anne, et al.
Publicado: (2013)

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
por: Legrier, M-E, et al.
Publicado: (2007)

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
por: Marangoni, E, et al.
Publicado: (2009)

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
por: Nemati, Fariba, et al.
Publicado: (2023)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Targeting Bcl-2/Bcl-X(L) Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
por: Némati, Fariba, et al.
Publicado: (2014)

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2012)

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2012)

Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials
por: Chateau-Joubert, Sophie, et al.
Publicado: (2021)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
por: Meyniel, Jean-Philippe, et al.
Publicado: (2010)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
por: Legrier, Marie-Emmanuelle, et al.
Publicado: (2016)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft
por: Legrier, M-E, et al.
Publicado: (2004)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
por: Groenewoud, Arwin, et al.
Publicado: (2023)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice
por: Leuraud, P, et al.
Publicado: (2003)

New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels
por: Sadacca, Benjamin, et al.
Publicado: (2017)

Author Correction: New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels
por: Sadacca, Benjamin, et al.
Publicado: (2018)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2017)

Evaluation of methods for amplification of picogram amounts of total RNA for whole genome expression profiling
por: Clément-Ziza, Mathieu, et al.
Publicado: (2009)

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019)

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification
por: Reyal, Fabien, et al.
Publicado: (2012)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application
por: Laas, Enora, et al.
Publicado: (2016)

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay
por: Mouttet, D., et al.
Publicado: (2016)

An avian embryo patient-derived xenograft model for preclinical studies of human breast cancers
por: Jarrosson, Loraine, et al.
Publicado: (2021)

Risk of Hormone Escape in a Human Prostate Cancer Model Depends on Therapy Modalities and Can Be Reduced by Tyrosine Kinase Inhibitors
por: Guyader, Charlotte, et al.
Publicado: (2012)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fp84shlj76f2kt19r3dp0sokrv